Key result
Review examines antithrombotic therapy guidelines, thrombosis pathophysiology, and current uncertainties after mitral valve surgery.
Why the study?
Guideline recommendations for antithrombotic therapy after mitral valve interventions are often extrapolated from aortic valve procedures, despite higher thrombotic risk in mitral valve disease.
This review highlights the pathophysiological basis for thrombosis in mitral valve conditions and discusses current guideline recommendations and uncertainties for antithrombotic therapy after mitral valve surgery.
Challenges reliance on aortic-derived data for mitral thrombosis; leaves open need for mitral-specific evidence before guideline updates.
The European and American guidelines offer recommendations for the management of antithrombotic medication following mitral valve interventions. Evidence to support recommendations is frequently extrapolated from studies of aortic valve procedures, despite thrombotic risk being substantially higher in mitral valve disease and mitral valve procedures. This review examines the pathophysiological basis for thrombosis in mitral valve conditions, the recommendations and evidence from the guidelines and current uncertainties.
No takes yet. Share an insight, caveat, or question.
Kirmani et al. (2026) conducted a review in Mitral valve conditions. Anti-thrombotic therapy was evaluated. This review examines the pathophysiological basis for thrombosis, guideline recommendations, and current uncertainties regarding antithrombotic therapy after mitral valve surgery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: